Skip to main navigation Skip to search Skip to main content

A probable drug-to-drug interaction between voriconazole and haloperidol in a slow metabolizer of CYP2C19

  • ILARIA MOTTA
  • , Andrea CALCAGNO
  • , LORENA BAIETTO
  • , ANTONIO D'AVOLIO
  • , Francesco Giuseppe DE ROSA
  • , Stefano BONORA

Research output: Contribution to journalArticlepeer-review

Abstract

We present a case of Aspergillus fumigatus renal abscess treated with voriconazole of a HIV-positive 43-year-old male patient. Following haloperidol treatment we observed an unexpected increase in voriconazole through concentrations and liver function tests. CYP2C19*2 loss of function allele was stated, an interaction probably explained by the introduction of haloperidol, a weak CYP3A4 inhibitor. Therapeutic drug monitoring and CYP2C19 genotyping may be suggested when administering voriconazole to complex patients.
Original languageEnglish
Pages (from-to)367-369
Number of pages3
JournalLE INFEZIONI IN MEDICINA
Volume23
Issue number4
Publication statusPublished - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'A probable drug-to-drug interaction between voriconazole and haloperidol in a slow metabolizer of CYP2C19'. Together they form a unique fingerprint.

Cite this